Abstract
Purpose
Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (ASA) are often prescribed concurrently in patients with nociceptive pain and cardiovascular comorbidity. NSAIDs and ASA inhibit the same COX-enzymes, and thus may interact. ASA’s cardioprotective antiplatelet effect is entirely COX-1 dependent. NSAIDs can be either non-COX-1 and COX-2 selective or COX-2 selective. The aim of this study was to examine the interaction between ASA and different selective and nonselective NSAIDs on thrombocyte function.
Methods
Single-blind, prospective, placebo-controlled, ex vivo, serial crossover trial of 3-day cycles separated by washout periods of at least 12 days in 30 healthy volunteers, evaluating interaction on ASA’s antithrombocyte effect by naproxen, ibuprofen, meloxicam, or etoricoxib taken 2 h before ASA. Ex vivo thrombocyte function, closure time (CT) in seconds, was measured using the Platelet Function Analyzer 100 (PFA-100). CT prolongation during a cycle reflects thrombocyte inhibitory effect. ASA nonresponse was defined as CT prolongation <40 % in the placebo cycle. ASA nonresponders were excluded. Wilcoxon signed-rank was used to evaluate NSAID effect on ASA-induced CT prolongation.
Results
Ibuprofen and naproxen inhibit ASA’s antithrombocyte effect below the nonresponse threshold. Etoricoxib and meloxicam do not cause relevant change in ASA thrombocyte inhibition. Naproxen has an inherent weak thrombocyte inhibitory action below the ASA response threshold.
Conclusions
COX-1 affinity determines the interaction between NSAIDs and ASA on thrombocyte adhesion and aggregation. Ibuprofen and naproxen, but not etoricoxib or meloxicam, taken 2 h before ASA, significantly inhibit ASA’s antithrombocyte effect.
Similar content being viewed by others
References
Al-Windi A (2005) Determinants of medicine use in a Swedish primary health care practice population. Pharmacoepidemiol Drug Saf 14(1):47–51
Nobili A, Franchi C, Pasina L et al (2011) Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf 20(5):488–496
Pilotto A, Franceschi M, Leandro G, Di Mario F (2003) NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 20(9):701–710
Dorp V, Beerthuis RK, Nugteren DH, Vonkeman H (1964) The biosynthesis of prostaglandins. Biochim Biophys Acta 90:204–207
Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265(28):16737–16740
Van Hecken A, Schwartz JI, Depre M et al (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40(10):1109–1120
Hawkey CJ (1999) COX-2 inhibitors. Lancet 353(9149):307–314
Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817
Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ (2009) The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 157(6):931–934
Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101(7):1060–1063
Capone ML, Sciulli MG, Tacconelli S et al (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45(8):1295–1301
Anzellotti P, Capone ML, Jeyam A et al (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 63(3):850–859
Kurth T, Glynn RJ, Walker AM et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108(10):1191–1195
MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357):573–574
Kimmel SE, Strom BL (2003) Giving aspirin and ibuprofen after myocardial infarction. BMJ 327(7427):1298–1299
Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM (2003) Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 327(7427):1322–1323
Patel TN, Goldberg KC (2004) Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 164(8):852–856
Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086
Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and Knee. Arthritis Care Res 64(4):455–474
Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, American Heart Association (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115(12):1634–1642
Rodriguez TAG, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52(20):1628–1636
Buerke M, Pittroff W, Meyer J, Darius H (1995) Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 130(3):465–472
Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B (2007) Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 120(2):161–172
Vonkeman HE, Van de Laar MA (2010) Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 39(4):294–312
Catella-Lawson F, Crofford LJ (2001) Cyclooxygenase inhibition and thrombogenicity. Am J Med 110(Suppl 3A):28S–32S
de Gaetano G, Cerletti C, Dejana E, Latini R (1985) Pharmacology of platelet inhibition in humans: implications of the salicilate-aspirin interaction. Circulation 72:1185–1193
Awa K, Satoh H, Hor S, Sawada Y (2012) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther 37:469–474
Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28(14):1702–1708
Favaloro EJ (2002) Clinical application of the PFA-100. Curr Opin Hematol 9(5):407–415
Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, De Gaetano G (2008) Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 99(1):14–26
Andersen K, Hurlen M, Arnesen H, Seljeflot I (2002) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108(1):37–42
Poulsen TS, Jorgensen B, Korsholm L, Bjorn LP, Haghfelt T, Mickley H (2007) Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 119(5):555–562
Gurbel PA, Tantry US (2007) Clopidogrel resistance? Thromb Res 120(3):311–321
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Clinical Trial Registration: Protocol ID APOMST003, EudraCT nr 2008-008954-22
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 665 kb)
Rights and permissions
About this article
Cite this article
Meek, I.L., Vonkeman, H.E., Kasemier, J. et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69, 365–371 (2013). https://doi.org/10.1007/s00228-012-1370-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-012-1370-y